Search results
14 kwi 2021 · The Oxford/AstraZeneca vaccine induced a stronger cellular immune response in elderly adults than the BioNTech/Pfizer shot, potentially providing more protection against severe Covid-19 and...
We identified 100 published peer-reviewed articles relevant to the Oxford–AstraZeneca vaccine or the ChAdOx technology (online supplemental files 1 and 2). Publication dates ranged from January 2002 to November 2020. The concordance between the two independent reviewers was 93.61%.
19 maj 2023 · This meta-analysis evaluated the Efficacy and Effectiveness of several COVID-19 vaccines, including AstraZeneca, Pfizer, Moderna, Bharat, and Johnson & Johnson, to better estimate their immunogenicity, benefits, or side effects.
The USA Phase 3 trial by AstraZeneca revealed that the vaccine had 79% efficacy among the symptomatic COVID-19 and 100% efficacy in the severe and hospitalized COVID-19 patients. The efficacy was identical across diverse ethnicity and ages, and showed 80% efficacy in participants aged ≥ 65 years .
10 gru 2020 · The Oxford/AstraZeneca vaccine this week became the first major COVID vaccine candidate to have efficacy results from phase 3 trials published in a peer-reviewed journal. The vaccine,...
25 mar 2021 · AstraZeneca says it plans to file for emergency-use authorization for the vaccine from the US Food and Drug Administration (FDA), and to submit the analysis of the trial for peer review...
13 maj 2021 · Abstract. Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. Design Test negative case-control study.
